Titre : Dose létale 50

Dose létale 50 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit and Disruptive Behavior Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Dose létale 50 : Questions médicales les plus fréquentes", "headline": "Dose létale 50 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Dose létale 50 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-21", "dateModified": "2025-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Dose létale 50" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Relation dose-effet des médicaments", "url": "https://questionsmedicales.fr/mesh/D004305", "about": { "@type": "MedicalCondition", "name": "Relation dose-effet des médicaments", "code": { "@type": "MedicalCode", "code": "D004305", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G07.690.936.500" } } }, "about": { "@type": "MedicalCondition", "name": "Dose létale 50", "alternateName": "Lethal Dose 50", "code": { "@type": "MedicalCode", "code": "D007928", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xia Yang", "url": "https://questionsmedicales.fr/author/Xia%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021, Nanning, Guangxi Zhuang Autonomous Region, China." } }, { "@type": "Person", "name": "Hirofumi Kurose", "url": "https://questionsmedicales.fr/author/Hirofumi%20Kurose", "affiliation": { "@type": "Organization", "name": "Department of Urology, Chikugo City Hospital, Chikugo, Japan." } }, { "@type": "Person", "name": "Keisuke Komiya", "url": "https://questionsmedicales.fr/author/Keisuke%20Komiya", "affiliation": { "@type": "Organization", "name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan." } }, { "@type": "Person", "name": "Naoyuki Ogasawara", "url": "https://questionsmedicales.fr/author/Naoyuki%20Ogasawara", "affiliation": { "@type": "Organization", "name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan." } }, { "@type": "Person", "name": "Kosuke Ueda", "url": "https://questionsmedicales.fr/author/Kosuke%20Ueda", "affiliation": { "@type": "Organization", "name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial.", "datePublished": "2024-02-16", "url": "https://questionsmedicales.fr/article/38434955", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyg.2024.1293244" } }, { "@type": "ScholarlyArticle", "name": "Attention deficit hyperactivity and oppositional defiant disorder symptoms in adolescence and risk of substance use disorders-A general population-based birth cohort study.", "datePublished": "2023-07-11", "url": "https://questionsmedicales.fr/article/37431766", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/acps.13588" } }, { "@type": "ScholarlyArticle", "name": "Parental Efficacy in Managing Smartphone Use of Adolescents with Attention-Deficit/Hyperactivity Disorder: Parental and Adolescent Related Factors.", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35954859", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph19159505" } }, { "@type": "ScholarlyArticle", "name": "Prenatal Cannabis Use and Offspring Attention Deficit Hyperactivity Disorder and Disruptive Behavior Disorders: A Retrospective Cohort Study.", "datePublished": "2024-10-15", "url": "https://questionsmedicales.fr/article/39400201", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DBP.0000000000001323" } }, { "@type": "ScholarlyArticle", "name": "Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders.", "datePublished": "2022-07-21", "url": "https://questionsmedicales.fr/article/35878505", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cpr.2022.102188" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques", "item": "https://questionsmedicales.fr/mesh/D010829" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes pharmacologiques et toxicologiques", "item": "https://questionsmedicales.fr/mesh/D002620" }, { "@type": "ListItem", "position": 4, "name": "Phénomènes toxicologiques", "item": "https://questionsmedicales.fr/mesh/D000069436" }, { "@type": "ListItem", "position": 5, "name": "Relation dose-effet des médicaments", "item": "https://questionsmedicales.fr/mesh/D004305" }, { "@type": "ListItem", "position": 6, "name": "Dose létale 50", "item": "https://questionsmedicales.fr/mesh/D007928" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Dose létale 50 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Dose létale 50", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Dose létale 50", "description": "Comment évaluer la DL50 d'une substance ?\nQuels tests sont utilisés pour mesurer la DL50 ?\nLa DL50 est-elle la même pour tous les organismes ?\nQuels facteurs influencent la DL50 ?\nComment la DL50 est-elle utilisée en recherche ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Dose létale 50", "description": "Quels symptômes indiquent une exposition à une DL50 ?\nLes symptômes varient selon la substance ?\nPeut-on prédire les symptômes d'une DL50 ?\nQuels sont les signes d'une intoxication aiguë ?\nComment reconnaître une intoxication par un produit chimique ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Dose létale 50", "description": "Comment prévenir l'exposition à des substances toxiques ?\nQuelles sont les mesures de sécurité en laboratoire ?\nLes réglementations aident-elles à prévenir les intoxications ?\nComment éduquer sur les dangers des substances toxiques ?\nLes étiquettes de produits chimiques sont-elles importantes ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Dose létale 50", "description": "Quel est le traitement d'une intoxication aiguë ?\nLes antidotes sont-ils toujours efficaces ?\nComment gérer une exposition à une DL50 ?\nQuels soins sont nécessaires après une exposition ?\nLa décontamination est-elle nécessaire ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Dose létale 50", "description": "Quelles complications peuvent survenir après une intoxication ?\nLes effets à long terme sont possibles ?\nComment surveiller les complications post-intoxication ?\nLes complications varient-elles selon la substance ?\nQuels sont les risques de réexposition ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Dose létale 50", "description": "Quels sont les facteurs de risque d'intoxication ?\nLes travailleurs sont-ils plus à risque ?\nComment l'âge influence-t-il le risque d'intoxication ?\nLes maladies préexistantes augmentent-elles le risque ?\nL'environnement joue-t-il un rôle dans l'intoxication ?", "url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la DL50 d'une substance ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La DL50 est déterminée par des études sur des groupes d'animaux exposés à différentes doses." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer la DL50 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de toxicité aiguë, souvent sur rongeurs, sont utilisés pour mesurer la DL50." } }, { "@type": "Question", "name": "La DL50 est-elle la même pour tous les organismes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, la DL50 varie selon l'espèce, le sexe et l'âge des organismes testés." } }, { "@type": "Question", "name": "Quels facteurs influencent la DL50 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La DL50 peut être influencée par la voie d'exposition, la durée et la sensibilité individuelle." } }, { "@type": "Question", "name": "Comment la DL50 est-elle utilisée en recherche ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour comparer la toxicité de différentes substances et établir des normes de sécurité." } }, { "@type": "Question", "name": "Quels symptômes indiquent une exposition à une DL50 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des nausées, vomissements, convulsions et coma." } }, { "@type": "Question", "name": "Les symptômes varient selon la substance ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent de la nature de la substance toxique et de la dose." } }, { "@type": "Question", "name": "Peut-on prédire les symptômes d'une DL50 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des modèles précliniques peuvent aider à prédire les symptômes, mais il y a des variations." } }, { "@type": "Question", "name": "Quels sont les signes d'une intoxication aiguë ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des troubles respiratoires, des douleurs abdominales et des troubles neurologiques." } }, { "@type": "Question", "name": "Comment reconnaître une intoxication par un produit chimique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La reconnaissance repose sur l'historique d'exposition et l'apparition rapide des symptômes." } }, { "@type": "Question", "name": "Comment prévenir l'exposition à des substances toxiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection, suivre les protocoles de sécurité et éduquer le personnel." } }, { "@type": "Question", "name": "Quelles sont les mesures de sécurité en laboratoire ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les mesures incluent l'utilisation de hottes, de gants et de formation sur les risques chimiques." } }, { "@type": "Question", "name": "Les réglementations aident-elles à prévenir les intoxications ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les réglementations sur l'utilisation des produits chimiques aident à réduire les risques." } }, { "@type": "Question", "name": "Comment éduquer sur les dangers des substances toxiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des formations régulières et des affichages d'information peuvent sensibiliser aux dangers." } }, { "@type": "Question", "name": "Les étiquettes de produits chimiques sont-elles importantes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles fournissent des informations essentielles sur les dangers et les mesures de sécurité." } }, { "@type": "Question", "name": "Quel est le traitement d'une intoxication aiguë ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'élimination de la substance, le soutien des fonctions vitales et des antidotes si disponibles." } }, { "@type": "Question", "name": "Les antidotes sont-ils toujours efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'efficacité des antidotes dépend de la substance et du moment de l'administration." } }, { "@type": "Question", "name": "Comment gérer une exposition à une DL50 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Il faut contacter un centre antipoison et suivre les protocoles d'urgence appropriés." } }, { "@type": "Question", "name": "Quels soins sont nécessaires après une exposition ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des soins de soutien, une surveillance continue et des traitements spécifiques peuvent être nécessaires." } }, { "@type": "Question", "name": "La décontamination est-elle nécessaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la décontamination est souvent nécessaire pour réduire l'absorption de la substance toxique." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une intoxication ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions organiques, des troubles neurologiques et des infections." } }, { "@type": "Question", "name": "Les effets à long terme sont possibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines substances peuvent causer des effets à long terme, comme des cancers ou des troubles chroniques." } }, { "@type": "Question", "name": "Comment surveiller les complications post-intoxication ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance médicale régulière est nécessaire pour détecter les complications précoces." } }, { "@type": "Question", "name": "Les complications varient-elles selon la substance ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications dépendent de la nature de la substance et de la dose reçue." } }, { "@type": "Question", "name": "Quels sont les risques de réexposition ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La réexposition peut aggraver les complications et augmenter le risque de maladies chroniques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'intoxication ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe, l'état de santé et l'environnement de travail." } }, { "@type": "Question", "name": "Les travailleurs sont-ils plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les travailleurs exposés à des produits chimiques sont souvent à risque accru d'intoxication." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il le risque d'intoxication ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les jeunes enfants et les personnes âgées sont plus vulnérables aux effets toxiques." } }, { "@type": "Question", "name": "Les maladies préexistantes augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies peuvent rendre les individus plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans l'intoxication ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un environnement pollué ou des conditions de travail dangereuses augmentent le risque." } } ] } ] }

Sources (10000 au total)

Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial.

Attention-Deficit/Hyperactivity Disorder (ADHD) affects 5% of children and 2.5% of adults worldwide. Comorbidities are frequent, and Oppositional Defiant Disorder (ODD) reaches 50%. Family environment... A clinical trial was designed to compare PT-online and face-to-face effects to a waiting list group. Outcomes were the ADHD and ODD symptoms, parental stress and styles, and quality of life. Families ... Parent training was effective in reducing symptoms of ADHD (...

Attention deficit hyperactivity and oppositional defiant disorder symptoms in adolescence and risk of substance use disorders-A general population-based birth cohort study.

Externalizing symptoms are associated with risk of future substance use disorder (SUD). Few longitudinal studies exist using general population-based samples which assess the spectrum of attention def... We aimed to study the associations between adolescent ADHD symptoms and subsequent SUD and additionally examine whether the risk of SUD is influenced by comorbid oppositional defiant disorder (ODD) sy... The Northern Finland Birth Cohort 1986 was linked to nationwide health care register data for incident SUD diagnoses until age 33 years (n = 6278, 49.5% male). ADHD/ODD-case status at age 16 years was... In all, 552 participants (8.8%) presented with ADHD case status at the age of 16 years, and 154/6278 (2.5%) were diagnosed with SUD during the follow-up. ADHD case status was associated with SUD durin... ADHD in adolescence was associated with incident SUD in those with and without symptoms of ODD. The association of ADHD and SUD persisted even after adjustment for a wide range of potential confounds....

Parental Efficacy in Managing Smartphone Use of Adolescents with Attention-Deficit/Hyperactivity Disorder: Parental and Adolescent Related Factors.

Parental management has an important role in preventing problematic smartphone use among adolescents with attention-deficit/hyperactivity disorder (ADHD). This study aimed to examine the parental fact...

Prenatal Cannabis Use and Offspring Attention Deficit Hyperactivity Disorder and Disruptive Behavior Disorders: A Retrospective Cohort Study.

To examine whether maternal cannabis use during early pregnancy is associated with offspring attention deficit hyperactivity disorder (ADHD) and disruptive behavior disorders (DBD).... We conducted a population-based retrospective birth cohort study of children (N = 141,570) born between 2011 and 2018 to pregnant individuals (N = 117,130) in Kaiser Permanente Northern California uni... The sample of pregnant individuals was 27.2% Asian/Pacific Islander, 5.7% Black, 24.5% Hispanic, and 38.8% non-Hispanic White, with a mean (SD) age of 30.9 (5.2) years; 4.6% screened positive for any ... Maternal prenatal cannabis use was not associated with an increased risk of offspring ADHD or DBD....

Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders.

The recent inclusion of callous-unemotional traits in the diagnostic criteria for serious conduct problems has led to renewed interest in more comprehensive integrations of the construct of psychopath...

Attention deficit and hyperactivity disorder disrupts selective mechanisms of action.

People with attention deficit and hyperactivity disorder (ADHD) present attentional and emotional deficits and show paradoxical qualities such as hyperfocus. Previous studies have reported errors, slo... Thirty French children and teenagers, 15 with ADHD and 15 neurotypical (NT), underwent a saccadic eye movement task. We conducted conventional analysis (movement duration, precision, velocity, RT) and... Saccade duration and velocity failed to differentiate the two groups, whereas amplitude was higher in ADHD than in NT participants. Saccade RT and variability were higher in ADHD than in NT participan... ADHD disrupts two mechanisms of action: it reduces the gain of the decision signal, thus explaining slowness and variability; it quickens the decision process of early responses at the origin of short... These premises and their interconnections explain previous observations and support the striatal-frontal wiring of ADHD, thus explaining ADHD complexity in its negative and positive manifestations....

Clinico-Demographic Profile of Children and Adolescents with Attention Deficit Hyperactivity Disorder Presenting to a Tertiary Care Centre: A Descriptive Cross-sectional Study.

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children. ADHD leads to significant impairment in overall functioning of the child. There is limited informat... This study retrospectively examines the records of children diagnosed with ADHD at the Child and Adolescent Psychiatry (CAP) Unit, Kanti Children's Hospital (KCH), Nepal. Approval for the study was gr... A total of 585 children were diagnosed with ADHD, with a mean age 7±3.04 years. The majority 501 (85.64%) were male, and 377 (64.44%) were from the school going age group (6 to 11 years). The prevalen... The study indicates that ADHD is highly prevalent in Nepal. Comorbidities like ASD and ID are frequently seen which further necessitates the need for structured assessments and multidisciplinary appro...

Treatment of childhood disruptive behavior disorders and callous-unemotional traits: a systematic review and two multilevel meta-analyses.

Children with callous-unemotional (CU) traits are at high lifetime risk of antisocial behavior. It is unknown if treatments for disruptive behavior disorders are as effective for children with CU trai... We systematically searched PsycINFO, PubMed, Cochran Library (Trials), EMBASE, MEDLINE, APA PsycNet, Scopus, and Web of Science. Eligible studies were randomized controlled trials, controlled trials, ... Sixty studies with 9,405 participants were included (M... DBD+CU children improve with treatment, but their greater DBD symptom severity requires specialized treatment modules that could be implemented alongside parenting programs. Conclusions are tempered b...